Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven(R) (eribulin) in the Treatment of Advanced Liposarcoma

Assessment ignores unprecedented overall survival benefit for eribulin in advanced liposarcoma[1] HATFIELD, England, September 4, 2016 -- (Healthcare Sales & Marketing Network) -- The German Institute for Quality and Efficiency in Health Care (IQWiG) h... Biopharmaceuticals, Oncology, Regulatory Eisai, Halaven, eribulin, Liposarcoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news